Onco Actu du 24 juillet 2015

(pour info : la parution de ce bulletin s'interrompt pendant 4 semaines)

	1. Biologie
Using CRISPR to investigate pancreatic cancer [Scope Blog] Winslow and his colleagues plan to use their approach to investigate not just the genetic mutations involved in the development of pancreatic cancer, but also those responsible for its progression and metastasis.
	5. Traitements
Oestrogen-suppressing drugs substantially reduce breast cancer deaths [The Institute of Cancer Research] The study, published in The Lancet today, is relevant to postmenopausal women with ER-positive breast cancer, which accounts for over 80% of cases which occur after the menopause.
Hitting the self-destruct switch – standing up to womb cancer with PARP inhibitors [Cancer Research UK] Many womb cancers contain faults in the genes that encode components of their DNA repair toolkits, and since the end of 2014, Dr Kristeleit and her team have been making preparations for a clinical trial to test a new PARP inhibitor in women with the disease.
Osteoporosis drug could benefit postmenopausal women with breast cancer [Cancer Research UK] "Before doctors give this drug to all post-menopausal women at high risk of breast cancer, more thorough clinical trials are needed".
A Systemic Immunomodulator IMM-101 Extends Survival and Maintains Quality of Life in the IMAGE1 Study [ESMO] In IMAGE 1, patients with advanced pancreatic cancer and WHO performance score 0-2 (n = 110) were assigned randomly to receive IMM-101 intradermally plus gemcitabine (n = 75) or gemcitabine alone (n = 35) for a 12-cycle maximum. The efficacy endpoint of primary interest was overall survival (OS).
Cheap osteoporosis drug could prevent a sixth of breast cancer deaths [The Guardian] Trials showed that the drugs stopped breast tumour cells from spreading to the bones, the most common site for secondary cancers, and reduced the risk of dying from the disease by 18% in the first ten years after diagnosis.
	5.2 Pharma
Amgen Submits Supplemental New Drug Application For Kyprolis® (Carfilzomib) In Relapsed Multiple Myeloma [Amgen] Filing Based on Data From Phase 3 Head-To-Head ENDEAVOR Study. Relapsed Multiple Myeloma Patients Treated With Kyprolis in Study Lived Twice as Long Without Disease Worsening.
European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indication in Europe [BMS] Variations include Opdivo in previously treated non-squamous, non-small cell lung cancer (NSCLC) and Opdivo in combination with Yervoy (ipilimumab) in advanced melanoma.
	5.2.1 Pharma - Partenariats
Merck extends Ablynx immuno-oncology relationship with heavily backloaded €4B deal [Fierce Biotech] Moses attributed Merck's interest in its technology to its ability to link two or three nanobodies together to target multiple immune checkpoints simultaneously.
	5.3 Traitements - FDA, EMA,...
Sunesis Pharmaceuticals Announces Regulatory Update [Sunesis] Company to Proceed Expeditiously With Marketing Authorization Application in Europe and Will Evaluate Regulatory and Clinical Strategies to Gain Marketing Approval in the U.S.
FDA seeks more clinical evidence on Sunesis Pharma cancer drug [Reuters] The FDA wanted the additional evidence before Sunesis files its marketing application for the drug, the company said in a statement on Thursday. The European Medicines Agency (EMA) however, gave the company the nod to submit a marketing application for vosaroxin, Sunesis said.
	5.4 Traitements - Economie
Doctors Press For Action To Lower 'Unsustainable' Prices For Cancer Drugs [NPR] "A lot of my patients cry — they're frustrated," says Dr. Ayalew Tefferi, a hematologist at the Mayo Clinic. "Many of them spend their life savings on cancer drugs and end up being bankrupt."
115 Doctors Propose This Solution For Terrifying Cancer Drug Prices [Forbes] Here’s the best idea they propose: An independent, government-chartered group that evaluated the value of drugs (option 1) would give insurance companies a powerful new negotiating tool. Like the U.S. Preventative Services Task Force, which evaluates screening, it would provide a basis for public discussion about these drugs, even if it had not power of its own.
	6. Lutte contre les cancers
Timothy Caulfield: Genetics and personalized medicine—where’s the revolution? [BMJ Blogs] All the available research points in the opposite direction. Studies have found that providing genetic risk information will not, long-term, help people quit smoking or lose weight. It will not encourage them to get cancer screening. And, more damning, it will not help individuals at risk for diabetes adopt a healthy lifestyle, even when that personalized, genetically informed advice is provided by experts.
Chemotherapy May Worsen End-of-Life Quality, Study Finds [NY Times] Some oncologists said that while the study tackled a difficult question carefully, patients and doctors should avoid generalizing based on its results.
	6.6 Publications
The UK Recommends ORCID [ORCID] This is a really strong recommendation. It not only indicates the usefulness of unique identifiers in information systems (such as in recommendation number 11, which advocates the increased use of ISNIs as organizational identifiers), it specifically suggests that ORCID iDs should be mandated in the national Research Excellence Framework (the REF).
	6.7.3 DMP
The tragedy of the electronic health record [The Pharos] Today’s EHRs impede workflow, are a roadblock to easy information transfer, and can cause significant downtime because of the need for specialized technical assistance. The EHR has unintentionally become more important than the patient.
	6.9 Controverses
Spilling the beans [The Economist] Failure to publish the results of all clinical trials is skewing medical science.